Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025IM-1021 and IM-3050 IND filings expected in first quarter of 2025Current cash expected to fund activities into 2026 BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments.“2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company’s leadership team,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “These accomplishments laid the groundwork for a productive start to 2024, including the acquisition of two promising assets and a successful financing.”Dr. Siegall continued, “We are focused on efficiently developing our four existing assets and expanding our pipeline. We expect
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Appoints Kinney Horn as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Kinney Horn as Chief Business OfficerBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $24.00 price target on the stock.MarketBeat
- Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]Yahoo! Finance
IMNM
Sec Filings
- 4/30/24 - Form 8-K
- 4/29/24 - Form 4
- 4/29/24 - Form 3
- IMNM's page on the SEC website